Gene regulation as a potential avenue for the treatment of neurodegenerative disorders

Bibliography

• Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10(Suppl):S10-7
   PubMed Web of Science ®Google Scholar
• Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:136-43
   PubMed Web of Science ®Google Scholar
• Honti V, Vécsei L. Genetic and molecular aspects of spinocerebellar ataxias. Neuropsychiatr Dis Treat 2005;1:125-33
   PubMedGoogle Scholar
• Lubarsky M, Juncos JL. Progressive supranuclear palsy: a current review. Neurologist 2008;14:79-88
   PubMed Web of Science ®Google Scholar
• Kertesz A. Frontotemporal dementia: a topical review. Cogn Behav Neurol 2008;21:127-33
   PubMed Web of Science ®Google Scholar
• Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-37
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363-83
   PubMed Web of Science ®Google Scholar
• de Lahunta A. Abiotrophy in domestic animals: a review. Can J Vet Res 1990;54:65-76
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association. 2008 Alzheimer's disease facts and figures. Alzheimers Dement 2008;4:110-33
   PubMed Web of Science ®Google Scholar
• Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003;66:255-65
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333-66
   PubMed Web of Science ®Google Scholar
• Bolton DC, McKinley MP, Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1982;218:1309-11
   PubMed Web of Science ®Google Scholar
• Meyer RK, Mckinley MP, Bowman KA, et al. Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci USA 1986;83:2310-4
   PubMed Web of Science ®Google Scholar
• Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999;96:11049-53
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40
   PubMed Web of Science ®Google Scholar
• Riek R, Hornemann S, Wider G, et al. NMR structure of the mouse prion protein domain PrP(121-321). Nature 1996;382:180-2
   PubMed Web of Science ®Google Scholar
• Brown DR, Qin K, Herms JW, et al. The cellular prion protein binds copper in vivo. Nature 1997;390;684-87
   Google Scholar
• Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501
   PubMed Web of Science ®Google Scholar
• De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000;113:1857-70
   PubMed Web of Science ®Google Scholar
• Kong GK, Miles LA, Crespi GA, et al. Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J 2008;37:269-79
   PubMed Web of Science ®Google Scholar
• Brown DR. Prion protein expression aids cellular uptake and veratridine-induced release of copper. J Neurosci Res 1999;58:717-25
   PubMed Web of Science ®Google Scholar
• Brown DR, Wong BS, Hafiz F, et al. Normal prion protein has an activity like that of superoxide dismutase. Biochem J 1999;344:1-5
   PubMed Web of Science ®Google Scholar
• Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997;77:1081-132
   PubMed Web of Science ®Google Scholar
• Yu S, Uéda K, Chan P. Alpha-synuclein and dopamine metabolism. Mol Neurobiol 2005;31:243-54
   PubMed Web of Science ®Google Scholar
• Hesketh S, Sassoon J, Knight R, et al. RElevated manganese levels in blood and CNS Occur prior to onset of clinical signs in scrapie and BSE. J Animal Sci 2007;85:1596-609
   PubMed Web of Science ®Google Scholar
• Hesketh S, Sassoon J, Knight R, Brown DR. Elevated manganese levels in blood and CNS in human prion disease. Mol Cell Neurosci 2008;37:590-8
   PubMed Web of Science ®Google Scholar
• Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75
   PubMed Web of Science ®Google Scholar
• Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998;19:339-45
   PubMed Web of Science ®Google Scholar
• Brown DR, Hafiz F, Glasssmith LL, et al. Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J 2000;19:1180-86
   PubMed Web of Science ®Google Scholar
• Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001;276:44284-96
   PubMed Web of Science ®Google Scholar
• Jobling MF, Huang X, Stewart LR, et al. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 2001;40:8073-84
   PubMed Web of Science ®Google Scholar
• Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008;15:223-40
   PubMed Web of Science ®Google Scholar
• Fischer M, Rülicke T, Raeber A, et al. Prion protein (PrP) with amino-proximal deletions restoring suceptability of PrP knockout mice to scrapie. EMBO J 1996;15:1255-64
   PubMed Web of Science ®Google Scholar
• Wood SJ, Wypych J, Steavenson S, et al. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274:19509-12
   PubMed Web of Science ®Google Scholar
• Rockenstein E, Hansen LA, Mallory M, et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001;914:48-56
   PubMed Web of Science ®Google Scholar
• Uversky VN, Li J, Souillac P, et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 2002;277:11970-8
   PubMed Web of Science ®Google Scholar
• Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004;63:805-11
   PubMed Web of Science ®Google Scholar
• Israeli E, Sharon R. Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J Neurochem 2009;108:465-74
   PubMed Web of Science ®Google Scholar
• Tsigelny IF, Bar-On P, Sharikov Y, et al. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 2007;274:1862-77
   PubMed Web of Science ®Google Scholar
• Mehta PD, Capone G, Jewell A, Freedland RL. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci 2007;254:22-7
   PubMed Web of Science ®Google Scholar
• Bodendorf U, Danner S, Fischer F, et al. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 2002;80:799-806
   PubMed Web of Science ®Google Scholar
• Chu CT, Plowey ED, Wang Y, et al. Location, location, location: altered transcription factor trafficking in neurodegeneration. J Neuropathol Exp Neurol 2007;66:873-83
   PubMed Web of Science ®Google Scholar
• Liou HC, Baltimore D. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol 1993;5:477-87
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-κB in the nervous system. Biochim Biophys Acta 2005;1745:287-99
   PubMed Web of Science ®Google Scholar
• Boissiere F, Hunot S, Faucheux B, et al. Nuclear translocation of NF-κB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997;8:2849-52
   PubMed Web of Science ®Google Scholar
• Terai K, Matsuo A, McGeer EG, McGeer PL. Enhancement of immunoreactivity for NF-κB in human cerebral infarctions. Brain Res 1996;739:343-49
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B, Uherek M, Wellmann H, et al. Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis. Proc Natl Acad Sci USA 1999;96:9409-14
   PubMed Web of Science ®Google Scholar
• Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 1997;94:7531-36
   PubMed Web of Science ®Google Scholar
• Migheli A, Piva R, Atzori C, et al. c-Jun, JNK/SAPK kinases and transcription factor NF-κB are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1997;56:1314-22
   PubMed Web of Science ®Google Scholar
• Chu CT, Levinthal DJ, Kulich SM, et al. Oxidative neuronal injury: the dark side of ERK1/2. Eur J Biochem 2004;271:2060-66
   PubMedGoogle Scholar
• Snyder H, Wolozin B. Pathological proteins in Parkinson's disease: focus on the proteasome. J Mol Neurosci 2004;24:425-42
   PubMed Web of Science ®Google Scholar
• Cuervo AM. Autophagy: many paths to the same end. Mol Cell Biochem 2004;263:55-72
   PubMed Web of Science ®Google Scholar
• Chu CT. Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol 2006;65:423-32
   PubMed Web of Science ®Google Scholar
• Grewal SS, Fass DM, Yao H, et al. Calcium and cAMP signalsdifferentially regulate cAMP-responsive element-binding protein function via a Rap1-extracellular signal-regulated kinase pathway. J Biol Chem 2000;275:34433-41
   PubMed Web of Science ®Google Scholar
• Chalovich EM, Zhu JH, Caltagarone J, et al. Functional repression of cAMP responseelement in 6-hydroxydopamine-treated neuronal cells. J Biol Chem 2006;281:17870-81
   PubMed Web of Science ®Google Scholar
• Forwood JK, Lam MH, Jans DA. Nuclear import of Creb and AP-1 transcription factors requires importin-β1 and Ran but is independent of importin-α. Biochemistry 2001;40:5208-17
   PubMed Web of Science ®Google Scholar
• Stevenson AS, Cartin L, Wellman TL, et al. Membrane depolarization mediates phosphorylation and nuclear translocation of CREB in vascular smooth muscle cells. Exp Cell Res 2001;263:118-30
   PubMed Web of Science ®Google Scholar
• Dai WJ, Funk A, Herdegen T, et al. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999;30:2391-8
   PubMed Web of Science ®Google Scholar
• Song DY, Yang YC, Shin DH, et al. Axotomy-induced dopaminergic neurodegeneration is accompanied with c-Jun phosphorylation and activation transcription factor 3 expression. Exp Neurol 2008;209:268-78
   PubMed Web of Science ®Google Scholar
• Neve RL, McPhie DL. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther 2006;111:99-113
   PubMed Web of Science ®Google Scholar
• Uchida Y, Nakano S, Gomi F, Takahashi H. Differential regulation of basic helix-loop-helix factors Mash1 and Olig2 by beta-amyloid accelerates both differentiation and death of cultured neural stem/progenitor cells. J Biol Chem 2007;282:19700-9
   PubMed Web of Science ®Google Scholar
• Büeler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell surface PrP protein. Nature 1992;356:577-82
   PubMed Web of Science ®Google Scholar
• Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-47
   PubMed Web of Science ®Google Scholar
• Brown DR, Herms J, Kretzschmar HA. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport 1994;5:2057-60
   PubMed Web of Science ®Google Scholar
• Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996;380:345-7
   PubMed Web of Science ®Google Scholar
• Brown DR. Microglia and Prion Disease. Microscop Res Tech 2001;54:71-80
   PubMed Web of Science ®Google Scholar
• Brown DR, Schmidt B, Kretzschmar HA. Effects of copper on survival of prion protein knockout neurones and glia. J Neurochem 1998;70:1686-93
   PubMed Web of Science ®Google Scholar
• Brown DR. Prion protein peptide neurotoxicity can be mediated by astrocytes. J Neurochem 1999;73:1105-13
   PubMed Web of Science ®Google Scholar
• Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302:871-4
   PubMed Web of Science ®Google Scholar
• White MD, Farmer M, Mirabile I, et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008;105:10238-43
   PubMed Web of Science ®Google Scholar
• Brown DR, Schmidt B, Kretzschmar HA. Expression of prion protein in PC12 is enhanced by exposure to oxidative stress. Int J Dev Neurosci 1997;15:961-72
   PubMed Web of Science ®Google Scholar
• Brown DR, Mohn CM. Astrocytic glutamate uptake and prion protein expression. Glia 1999;25:282-92
   PubMed Web of Science ®Google Scholar
• Wong BS, Brown DR, Pan T, et al. Oxidative impairment in scrapie-infected mice is associated with brain metal perturbations and altered ani-oxidantion activities. J Neurochem 2001;79:689-98
   PubMed Web of Science ®Google Scholar
• Thackray AM, Knight R, Haswell SJ, et al. Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J 2002;362:253-58
   PubMed Web of Science ®Google Scholar
• Brown DR, Clive C, Haswell SJ. Anti-oxidant activity related to copper binding of native prion protein. J Neurochem 2001;76:69-76
   PubMed Web of Science ®Google Scholar
• Brown DR, Nicholas R St J, Canevari L. Lack of prion protein expression results in a neuronal phenotype sensitive to stress. J Neurosci Res 2002;67:211-24
   PubMed Web of Science ®Google Scholar
• Brown DR, Schmidt B, Groschup MH, Kretzschmar HA. Prion protein expression in muscle cells and toxicity of a prion protein fragment. Eur J Cell Biol 1998;75:29-37
   PubMed Web of Science ®Google Scholar
• Haigh CL, Wright JA, Brown DR. Regulation of prion protein expression by non coding regions of the Prnp gene. J Mol Biol 2007;368:915-27
   PubMed Web of Science ®Google Scholar
• Rybner C, Hillion J, Sahraoui T, et al. All-trans retinoic acid down-regulates prion protein expression independently of granulocyte maturation. Leukemia 2002;16:940-8
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA 2008;105:10907-12
   PubMed Web of Science ®Google Scholar
• Chiba-Falek O, Kowalak JA, Smulson ME, Nussbaum RL. Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet 2005;76:478-92
   PubMed Web of Science ®Google Scholar
• Clough RL, Stefanis L. A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J 2007;21:596-607
   PubMed Web of Science ®Google Scholar
• Yang YX, Latchman DS. Nurr1 transcriptionally regulates the expression of alpha-synuclein. Neuroreport 2008;19:867-71
   PubMed Web of Science ®Google Scholar
• Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001;10:3101-9
   PubMed Web of Science ®Google Scholar
• Fan Y, Limprasert P, Murray IV, et al. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum Mol Genet 2006;15:3002-11
   PubMed Web of Science ®Google Scholar
• Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 1998;95:4013-18
   PubMed Web of Science ®Google Scholar
• Kim KS, Kim CH, Hwang YD, et al. Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem 2003;85:622-34
   PubMed Web of Science ®Google Scholar
• Sacchetti P, Mitchell TR, Granneman JG, Bannon MJ. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 2001;76:1565-72
   PubMed Web of Science ®Google Scholar
• Sakurada K, Ohshima-Sakurada M, Palmer TD, Gage FH. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 1999;126:4017-26
   PubMed Web of Science ®Google Scholar
• Chu Y, Kompoliti K, Cochran EJ, et al. Age-related decreases in Nurr1 immunoreactivity in the human substantianigra. J Comp Neurol 2002;450:203-14
   PubMed Web of Science ®Google Scholar
• Chu YW, Le K, Kompoliti J, et al. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006;494:495-514
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Ray WJ, Glantschnig H, et al. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol Cell Biol 2007;27:7486-96
   PubMed Web of Science ®Google Scholar
• Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002;8:497-511
   PubMed Web of Science ®Google Scholar
• Dean B. Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgrad Med 2002;78:142-8
   Web of Science ®Google Scholar
• Evin G, Kenche VB. BACE inhibitors as potential therapeutics for Alzheimer's disease. Rec Pat CNS Drug Discov 2007;2:188-99
   PubMedGoogle Scholar
• Orlacchio A, Bernardi G, Orlacchio A, Martino S. RNA interference as a tool for Alzheimer's disease therapy. Mini Rev Med Chem 2007;7:1166-76
   PubMed Web of Science ®Google Scholar
• Hills ID, Vacca JP. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Dev 2007;10:383-91
   PubMed Web of Science ®Google Scholar
• Guo T, Hobbs DW. Development of BACE1 inhibitors for Alzheimer's disease. Curr Med Chem 2006;13:1811-29
   PubMed Web of Science ®Google Scholar
• Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 2007;4:412-7
   PubMed Web of Science ®Google Scholar
• Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog Neurobiol 2006;79:95-111
   PubMed Web of Science ®Google Scholar
• Wen Y, Yu WH, Maloney B, et al. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 2008;57:680-90
   PubMed Web of Science ®Google Scholar
• O'Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008;60:988-1009
   PubMed Web of Science ®Google Scholar
• Tamagno E, Guglielmotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 2008;104:683-95
   PubMed Web of Science ®Google Scholar